Baseline characteristics
| LABA/LAMA-FDC-based therapy (N = 3815) | Standard therapy without LABA/LAMA FDC (N = 1408) | Total Population (N = 5223) | |
|---|---|---|---|
| Male,% | 59.4 | 57.3 | 58.9 |
| Height (cm), mean | 170.4 | 170.0 | 170.3 |
| Weight (kg), mean | 80.3 | 80.6 | 80.4 |
| BMI (kg/m2), mean | 27.6 | 27.8 | 27.7 |
| Age (years), mean | 66.6 | 66.6 | 66.6 |
| Age groups, < 65 65–75 >75 | 42.7% 35.8% 21.5% | 42.8% 33.6% 23.7% | 42.7% 35.2% 22.1% |
| FEV1 predicted (litre), mean | 1.7 | 1.7 | 1.7 |
| Symptoms | |||
| CAT total score, mean | 18.9 | 18.6 | 18.8 |
| mMRC total score, mean | 1.7 | 1.7 | 1.7 |
| Airflow limitation according to GOLD 20111 ,% | |||
| Mild | 19.1 | 23.4 | 20.3 |
| Moderate | 51.7 | 50.9 | 51.5 |
| Severe | 25.2 | 22.7 | 24.5 |
| Very severe | 4.0 | 3.1 | 3.7 |
| COPD severity according to GOLD 20111,% | |||
| GOLD A | 9.3 | 10.1 | 9.5 |
| GOLD B | 45.2 | 47.6 | 45.8 |
| GOLD C | 3.4 | 2.8 | 3.2 |
| GOLD D | 42.2 | 39.6 | 41.5 |
CAT = COPD Assessment Test; mMRC = modified Medical Research Council dyspnoea scale